$186.46
+2.0%ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME)to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; and HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies. The company markets its products primarily to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Outstanding operational efficiency. The company generates substantial profit from core operations.
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
RMD โข NYSE
| ResMed Inc. Income Statement | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | Jun 2009 | Jun 2008 | Jun 2007 | Jun 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
5.1B | 4.7B | 4.2B | 3.6B | 3.2B | 3B | 2.6B | 2.3B | 2.1B | 1.8B | 1.7B | 1.6B | 1.5B | 1.4B | 1.2B | 1.1B | 920.7M | 835.4M | 716.3M | 607M | |
GROSS PROFIT | ||||||||||||||||||||
(2.1B) | (2B) | (1.9B) | (1.6B) | (1.4B) | (1.2B) | (1.1B) | (978M) | (865M) | (772.2M) | (667.5M) | (565.2M) | (573.8M) | (547.8M) | (501.8M) | (436.9M) | (366.9M) | (341.6M) | (331.8M) | (230.1M) | |
3.1B | 2.7B | 2.4B | 2B | 1.8B | 1.7B | 1.5B | 1.4B | 1.2B | 1.1B | 1B | 989.8M | 940.7M | 820.7M | 741.3M | 655.5M | 553.8M | 493.8M | 384.5M | 376.9M | |
OPERATING INCOME | ||||||||||||||||||||
(1.4B) | (1.3B) | (1.2B) | (1B) | (935.4M) | (908.7M) | (957.3M) | (820.3M) | (775.9M) | (637.5M) | (602.2M) | (584.7M) | (585.8M) | (525.3M) | (473.4M) | (412.1M) | (363.5M) | (348.4M) | (294.3M) | (244.5M) | |
(991M) | (917.1M) | (874M) | (739.4M) | (670.4M) | (676.7M) | (645M) | (600.4M) | (554M) | (488.1M) | (472.6M) | (450.4M) | (430.8M) | (401.6M) | (371.2M) | (328.9M) | (289.9M) | (278.1M) | (237.3M) | (200.2M) | |
(331.3M) | (307.5M) | (287.6M) | (253.6M) | (225.3M) | (201.9M) | (180.7M) | (155.1M) | (144.5M) | (118.7M) | (114.9M) | (118.2M) | (120.1M) | (109.7M) | (92M) | (75.2M) | (63.1M) | (60.5M) | (50.1M) | (37.2M) | |
1.7B | 1.3B | 1.1B | 1B | 903.7M | 809.7M | 579.3M | 541.8M | 425.8M | 429M | 409.2M | 405.1M | 354.8M | 294.4M | 266.9M | 240.4M | 190.3M | 143M | 90.2M | 131.3M | |
PRE-TAX INCOME | ||||||||||||||||||||
(12.6M) | (45.7M) | (47.4M) | (22.3M) | (24M) | (40.4M) | (36.2M) | (28.4M) | (28.2M) | (11.2M) | (5.8M) | (6.1M) | (6.4M) | (4.8M) | (1.8M) | (10.1M) | (10.1M) | (10.1M) | (1.3M) | (1.3M) | |
-12.6M | -45.7M | -47.4M | -22.3M | -23.6M | -39.4M | -33.9M | -12M | -11.2M | 5.7M | 20.4M | 25.1M | 32.5M | 29.1M | 26M | 14M | 10.2M | 0.0 | 0.0 | 0.0 | |
(47.3M) | (110.7M) | (62.1M) | (31.1M) | (39.8M) | (30.1M) | (131.7M) | (64.8M) | (77.5M) | (30.8M) | (14.7M) | (16.1M) | (34.9M) | (14M) | (10.1M) | (8M) | (10.6M) | (9.8M) | (6.9M) | (7.1M) | |
-7.8M | -55.1M | -30.2M | -39.8M | -20M | -76.6M | -60.4M | -20.5M | -7.1M | 10.6M | 26.7M | 26M | 30.3M | 37.5M | 36.8M | 20.2M | 11.4M | 14.9M | 7.8M | 2.1M | |
1.7B | 1.3B | 1.1B | 960.5M | 883.7M | 733.1M | 518.8M | 521.3M | 418.7M | 439.6M | 435.9M | 431.1M | 385.1M | 331.9M | 303.7M | 260.6M | 201.7M | 157.9M | 98M | 133.4M | |
NET INCOME | ||||||||||||||||||||
(276.8M) | (243.8M) | (204.1M) | (181M) | (409.2M) | (111.4M) | (114.3M) | (205.7M) | (76.5M) | (87.2M) | (83M) | (85.8M) | (78M) | (77.1M) | (76.7M) | (70.5M) | (55.2M) | (47.6M) | (31.7M) | (45.2M) | |
1.4B | 1B | 897.6M | 779.4M | 474.5M | 621.7M | 404.6M | 315.6M | 342.3M | 352.4M | 352.9M | 345.3M | 307.1M | 254.9M | 227M | 190.1M | 146.4M | 110.3M | 66.3M | 88.2M |
RMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 01, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 30, 2026 | April 30, 2026 | 2026 | |
10-Q 10-Q 2025 Q4 Q4 | January 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 29, 2026 | January 29, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 20, 2025 | November 19, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 31, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 30, 2025 | October 30, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | October 02, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 18, 2025 | August 15, 2025 | 2025 |
Continue your RMD research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.